Australia markets close in 4 hours 41 minutes

CytomX Therapeutics, Inc. (CTMX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.6800+0.0100 (+0.60%)
At close: 04:00PM EDT
1.7000 +0.02 (+1.19%)
After hours: 07:24PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 113.11M
Enterprise value -47.42M
Trailing P/E N/A
Forward P/E 41.67
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.22
Price/book (mrq)5.04
Enterprise value/revenue -0.47
Enterprise value/EBITDA 11.01

Trading information

Stock price history

Beta (5Y monthly) 1.02
52-week change 33.73%
S&P500 52-week change 323.06%
52-week high 32.8550
52-week low 31.0400
50-day moving average 32.0324
200-day moving average 31.6046

Share statistics

Avg vol (3-month) 3928.73k
Avg vol (10-day) 3696.91k
Shares outstanding 567.73M
Implied shares outstanding 667.73M
Float 853.83M
% held by insiders 11.19%
% held by institutions 148.54%
Shares short (28 Mar 2024) 43.32M
Short ratio (28 Mar 2024) 42.17
Short % of float (28 Mar 2024) 44.95%
Short % of shares outstanding (28 Mar 2024) 44.91%
Shares short (prior month 29 Feb 2024) 41.64M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -0.56%
Operating margin (ttm)-2.28%

Management effectiveness

Return on assets (ttm)-1.75%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)101.21M
Revenue per share (ttm)1.37
Quarterly revenue growth (yoy)32.20%
Gross profit (ttm)N/A
EBITDA -4.31M
Net income avi to common (ttm)-569k
Diluted EPS (ttm)-0.0100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)174.51M
Total cash per share (mrq)2.58
Total debt (mrq)13.97M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.17
Book value per share (mrq)-0.70

Cash flow statement

Operating cash flow (ttm)-56.03M
Levered free cash flow (ttm)43.66M